MLST8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL135767	0.75	17/20
SCHEMBL154745	0.75	17/20
SCHEMBL154746	0.75	17/20
Cc-115 (SCHEMBL135765)	0.72	17/20
SCHEMBL151975	0.69	17/20
SCHEMBL154325	0.69	17/20
SCHEMBL155833	0.69	17/20
SCHEMBL157649	0.69	17/20
SCHEMBL138444	0.56	17/20
SCHEMBL153800	0.76	16/20
SCHEMBL153801	0.76	16/20
SCHEMBL154386	0.76	16/20
SCHEMBL136142	0.75	16/20
SCHEMBL152773	0.75	16/20
SCHEMBL152774	0.75	16/20
SCHEMBL153831	0.75	16/20
SCHEMBL153832	0.75	16/20
SCHEMBL155714	0.75	16/20
SCHEMBL138204	0.74	16/20
SCHEMBL138084	0.72	16/20

Clinical trials — most relevant to MLST8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Doxycycline In Lymphangioleiomyomatosis (LAM)	PHASE4	COMPLETED
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris	PHASE4	UNKNOWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	PHASE2	RECRUITING
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants	PHASE1/PHASE2	COMPLETED
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM	PHASE2	UNKNOWN
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas	PHASE2	COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer	PHASE2	COMPLETED
Feasibility of [11C]Acetate-PET in LAM and TSC	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	WITHDRAWN
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer	nan	WITHDRAWN
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MLST8 binder may also engage these)

Protein	Name	Similarity
Q17QU5	—	1.000	Q17QU5 →
Q6PA72	—	1.000	Q6PA72 →
Q9DCJ1	—	1.000	Q9DCJ1 →
Q9Z2K5	—	1.000	Q9Z2K5 →
Q803V5	—	1.000	Q803V5 →
Q5I0B4	—	1.000	Q5I0B4 →
Q96MX6	—	0.963	Q96MX6 →
A0A1L8EXB5	—	0.958	A0A1L8EXB5 →
C1BK83	—	0.957	C1BK83 →
Q8BGF3	—	0.956	Q8BGF3 →
Q9FKT5	—	0.956	Q9FKT5 →
Q8AVT9	—	0.956	Q8AVT9 →
A4IIX9	—	0.955	A4IIX9 →
Q9AYE4	—	0.954	Q9AYE4 →
Q8CBE3	—	0.954	Q8CBE3 →
Q9YGY3	—	0.953	Q9YGY3 →
Q6DDF0	—	0.953	Q6DDF0 →
BUB3	Mitotic checkpoint protein BUB3	0.952	landscape →
Q6TGU2	—	0.952	Q6TGU2 →
Q9R0Q6	—	0.952	Q9R0Q6 →
Q5RB58	—	0.951	Q5RB58 →
Q29RZ9	—	0.951	Q29RZ9 →
Q99PD4	—	0.950	Q99PD4 →
Q92747	—	0.950	Q92747 →
Q5R650	—	0.950	Q5R650 →
Q9Y2I8	—	0.949	Q9Y2I8 →
Q561Y0	—	0.949	Q561Y0 →
Q9WVA3	—	0.949	Q9WVA3 →
Q1JQB2	—	0.948	Q1JQB2 →
Q1JP79	—	0.948	Q1JP79 →